CytomX Therapeutics (CTMX) Share-based Compensation (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Share-based Compensation came in at $4.7 million in Q1 2026, up 134.36% YoY from $2.0 million in Q1 2025, and up 218.19% on a QoQ basis from $1.5 million in Q4 2025.
CytomX Therapeutics (CTMX) Share-based Compensation (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Share-based Compensation data on file, last reported at $4.7 million in Q1 2026.
- Quarterly Share-based Compensation rose 134.36% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 7.3% YoY) and the FY2025 annual result came in at $7.3 million, down 4.8% from the prior year.
- Share-based Compensation grew to $4.7 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.7 million in Q1 2026 to a low of -$10.5 million in Q4 2022.
- A 5-year average of $1.2 million and a median of $1.9 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation sank 396.28% — and 2026, when it jumped 134.36%.
- Tracing CTMX's Share-based Compensation over 5 years: stood at -$10.5 million in 2022, then jumped by 124.3% to $2.6 million in 2023, then fell by 26.18% to $1.9 million in 2024, then fell by 21.5% to $1.5 million in 2025, then soared by 218.19% to $4.7 million in 2026.
- The last three Share-based Compensation figures came in at $4.7 million (Q1 2026), $1.5 million (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.58 Mn |
| Jun 30, 2026 | 2.58 Mn |
| Mar 31, 2026 | 4.71 Mn |
| Mar 31, 2026 | 4.71 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 2.01 Mn |
| Mar 31, 2025 | 2.01 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Mar 31, 2024 | 1.91 Mn |